# Role of Endothelin-A (ETA) and Endothelin-B (ETB) Receptors in the Vasodilatory Response to Endothelin-3 (ET-3)

> **NCT01100736** · EARLY_PHASE1 · COMPLETED · sponsor: **University of Edinburgh** · enrollment: 10 (estimated)

## Conditions studied

- Pulmonary Arterial Hypertension
- Vasodilation
- Vasoconstriction

## Interventions

- **DRUG:** Bosentan
- **DRUG:** Sitaxsentan
- **DRUG:** Placebo
- **BIOLOGICAL:** Endothelin-3

## Key facts

- **NCT ID:** NCT01100736
- **Lead sponsor:** University of Edinburgh
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-09
- **Final completion:** 2010-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2015-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01100736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01100736, "Role of Endothelin-A (ETA) and Endothelin-B (ETB) Receptors in the Vasodilatory Response to Endothelin-3 (ET-3)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01100736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*